{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:54:37Z","timestamp":1792652077520,"version":"4.5.0"},"reference-count":21,"publisher":"Informa UK Limited","issue":"4","license":[{"start":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T00:00:00Z","timestamp":1705968000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016480","name":"Constellation Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016480","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Leukemia &amp; Lymphoma"],"published-print":{"date-parts":[[2024,3,20]]},"DOI":"10.1080\/10428194.2023.2300710","type":"journal-article","created":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T15:54:29Z","timestamp":1706025269000},"page":"503-510","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":17,"title":["Results from phase 1 of the MANIFEST clinical trial to evaluate the safety and tolerability of pelabresib in patients with myeloid malignancies"],"prefix":"10.1080","volume":"65","author":[{"given":"Eytan M.","family":"Stein","sequence":"first","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir T.","family":"Fathi","sequence":"additional","affiliation":[{"name":"Leukemia Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wael A.","family":"Harb","sequence":"additional","affiliation":[{"name":"Horizon Oncology and Research Center, Lafayette, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gozde","family":"Colak","sequence":"additional","affiliation":[{"name":"Constellation Pharmaceuticals, Inc., a MorphoSys Company, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Fusco","sequence":"additional","affiliation":[{"name":"Constellation Pharmaceuticals, Inc., a MorphoSys Company, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James K.","family":"Mangan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Blood and Marrow Transplantation, University of California San Diego, La Jolla, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,1,23]]},"reference":[{"key":"e_1_3_7_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4286"},{"key":"e_1_3_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2014.05.016"},{"key":"e_1_3_7_4_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1411701111"},{"key":"e_1_3_7_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34205"},{"key":"e_1_3_7_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000001"},{"key":"e_1_3_7_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14143557"},{"key":"e_1_3_7_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cdd.4401874"},{"key":"e_1_3_7_9_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b01882"},{"key":"e_1_3_7_10_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0029"},{"key":"e_1_3_7_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01972"},{"key":"e_1_3_7_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells10051034"},{"key":"e_1_3_7_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-152040"},{"key":"e_1_3_7_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33590"},{"key":"e_1_3_7_15_1","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.CRC-22-0060"},{"key":"e_1_3_7_16_1","volume-title":"BET inhibitor pelabresib decreases inflammatory cytokines, improves bone marrow fibrosis and function, and demonstrates clinical response irrespective of mutation status in myelofibrosis patients","author":"Keller P","year":"2021","unstructured":"Keller P, Cui J, Mertz J, et\u00a0al. BET inhibitor pelabresib decreases inflammatory cytokines, improves bone marrow fibrosis and function, and demonstrates clinical response irrespective of mutation status in myelofibrosis patients. Presented at the European Hematology Association; June 9\u201317, 2021; virtual congress."},{"key":"e_1_3_7_17_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.778741"},{"key":"e_1_3_7_18_1","unstructured":"ClinicalTrials.gov. A phase 2 study of CPI-0610 with and without ruxolitinib in patients with myelofibrosis. NCT02158858. 2022. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02158858"},{"key":"e_1_3_7_19_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-4071"},{"key":"e_1_3_7_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.2292"},{"key":"e_1_3_7_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-01180-1"},{"key":"e_1_3_7_22_1","unstructured":"ClinicalTrials.gov. Phase 3 study of pelabresib (CPI-0610) in myelofibrosis (MF) (MANIFEST-2). NCT04603495. 2022. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04603495"}],"container-title":["Leukemia &amp; Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428194.2023.2300710","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T21:00:55Z","timestamp":1727211655000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10428194.2023.2300710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,23]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,3,20]]}},"alternative-id":["10.1080\/10428194.2023.2300710"],"URL":"https:\/\/doi.org\/10.1080\/10428194.2023.2300710","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"value":"1042-8194","type":"print"},{"value":"1029-2403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,23]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-09-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-03","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}